Fabio Cury | Gerald Bronfman Department ...

Dr. Fabio Cury, MD

Claim this profile

McGill University Health Centre-Cedars Cancer Centre

Studies Prostate Cancer
Studies Soft Tissue Sarcoma
6 reported clinical trials
13 drugs studied

Area of expertise

1

Prostate Cancer

Fabio Cury, MD has run 5 trials for Prostate Cancer. Some of their research focus areas include:

metastatic
localized
testosterone
2

Soft Tissue Sarcoma

Fabio Cury, MD has run 1 trial for Soft Tissue Sarcoma. Some of their research focus areas include:

Stage IV

Affiliated Hospitals

Image of trial facility.

McGill University Health Centre-Cedars Cancer Centre

Image of trial facility.

McGill University Health Center

Clinical Trials Fabio Cury, MD is currently running

Image of trial facility.

SBRT

for Prostate Cancer

It is a phase I study of radical hypofractionation delivering one single fraction of SBRT in patients with low- and favorable intermediate-risk prostate cancer that will undergo placement of the SpaceOAR hydrogel prior to treatment. Our hypothesis is that treatments can be safely delivered in one single fraction using SBRT provided the separation between the prostate and rectum is increased using the hydrogel

Recruiting

1 award

N/A

6 criteria

Image of trial facility.

Hypofractionated Radiation Therapy + Eligard

for Prostate Cancer

Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk tumour characteristic. Although surgery can be curative in patients evidencing pathological high-risk disease (extracapsular extension, seminal vesicle involvement, positive surgical margins), a large proportion will develop biochemical failure within years from the surgical procedure. The failure rate is even more pronounced in those patients that present with high prostate specific antigen (PSA) levels, pT3 disease, positive margins and Gleason score ≥8 with an estimated 75% failure rate at 10 years. Post-operative radiotherapy (RT) has been shown in three randomized trials to significantly decrease the biochemical failure rate and in one of the trials a survival benefit was also seen with the addition of post-operative RT and is considered by many investigators standard therapy in patients with pathological high-risks factors even in absence of biochemical failure.

Recruiting

2 awards

Phase 2

10 criteria

More about Fabio Cury, MD

Clinical Trial Related

7 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Fabio Cury, MD has experience with

  • SBRT
  • Hypofractionation
  • Eligard
  • Postop Hypofractionated Radiation Therapy
  • Enzalutamide
  • Goserelin Acetate

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Fabio Cury, MD specialize in?

Is Fabio Cury, MD currently recruiting for clinical trials?

Are there any treatments that Fabio Cury, MD has studied deeply?

What is the best way to schedule an appointment with Fabio Cury, MD?

What is the office address of Fabio Cury, MD?

Is there any support for travel costs?